Preclinical CAR-T testing in ALL

Strengthen efficacy and safety evidence using relevant preclinical models and translational data.

Scientific visual associated with Preclinical CAR-T testing in ALL
Validation using preclinical models expertise — OPALE
01Carnot instituteOPALE
02Development stagePreclinical validation
03Main expertiseValidation using preclinical models
04Relevant fieldsOncology

Offer overview

What this offer helps you achieve

Strengthen efficacy and safety evidence using relevant preclinical models and translational data.

Scientific and technical scope

Preclinical testing of CAR-T cells for the treatment of T/B acute lymphoblastic leukemia (ALL): Preclinical testing the efficacy of CAR-T-cell therapy in ALL, to assess the impact of CAR-T-cells on leukemia cells and lymphocyte development. Availability of PDX models derived from patients with T/B-ALL (pediatric)
01

Capabilities mobilised

Therapeutic areasValidation using preclinical models
02

Application fields

Oncology

Discuss this offer

Could this capability strengthen your R&D programme?

Present your scientific, technical or clinical need and identify the most relevant route to collaboration.